Avelumab + Paclitaxel
Phase 2UNKNOWN 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Angiosarcoma Metastatic
Conditions
Angiosarcoma Metastatic
Trial Timeline
Jun 1, 2018 → May 1, 2023
NCT ID
NCT03512834About Avelumab + Paclitaxel
Avelumab + Paclitaxel is a phase 2 stage product being developed by Merck for Angiosarcoma Metastatic. The current trial status is unknown. This product is registered under clinical trial identifier NCT03512834. Target conditions include Angiosarcoma Metastatic.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03512834 | Phase 2 | UNKNOWN |
Competing Products
6 competing products in Angiosarcoma Metastatic
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Eribulin | Eisai | Phase 2 | 52 |
| Pembrolizumab plus Lenvatinib | Merck | Phase 2 | 52 |
| Pazopanib + Paclitaxel | Novartis | Phase 2 | 52 |
| regorafenib | Bayer | Phase 2 | 49 |
| Vusolimogene Oderparepvec (VO) + Pembrolizumab | Replimune | Phase 2 | 44 |
| AGEN2034 + AGEN1884 | Agenus | Phase 2 | 44 |